You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 6, 2025

Drug Price Trends for MS CONTIN ER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for MS CONTIN ER

Average Pharmacy Cost for MS CONTIN ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
MS CONTIN ER 30 MG TABLET 42858-0631-01 8.32796 EACH 2024-12-18
MS CONTIN ER 30 MG TABLET 42858-0631-01 8.32796 EACH 2024-11-20
MS CONTIN ER 15 MG TABLET 42858-0515-01 4.40368 EACH 2024-06-03
MS CONTIN ER 30 MG TABLET 42858-0631-01 8.38027 EACH 2024-06-03
MS CONTIN ER 15 MG TABLET 42858-0515-01 4.04004 EACH 2024-05-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

MS CONTIN ER Market Analysis and Financial Projection

Market Analysis and Price Projections for MS CONTIN ER

Overview of MS CONTIN ER

MS CONTIN ER, or Morphine Sulfate Controlled-Release Tablets, is a long-acting opioid formulation designed for the management of moderate to severe pain that requires continuous, around-the-clock opioid analgesia. This medication is particularly indicated for opioid-tolerant patients and is not intended for use as a PRN (as needed) analgesic or for pain in the immediate postoperative period[3].

Market Size and Growth

The global opioids market, which includes MS CONTIN ER, was valued at approximately USD 22.8 billion in 2022. This market is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 1.4% from 2023 to 2030. The extended-release (ER)/long-acting opioids segment, where MS CONTIN ER falls, accounted for the largest revenue share of 54.2% in 2022 and is expected to grow at a CAGR of 1.7% during the forecast period[4].

Regional Market Share

North America currently leads the global opioids market with the highest market share, accounting for approximately 45.13% in 2023. However, the Asia-Pacific region is expected to expand at the fastest CAGR during the forecast period, driven by increasing healthcare expenditure and a growing patient population[1].

Application and Usage

MS CONTIN ER is primarily used for pain relief, which is the largest application segment within the opioids market. The pain relief segment held a significant market share of 24% in 2023. Additionally, the anesthesia segment, where opioids like MS CONTIN ER are used to provide analgesia and supplement sedation during general anesthesia, is expected to grow at a CAGR of 2.0% over the forecast period[1][4].

Route of Administration

The oral route of administration, which includes MS CONTIN ER tablets, is a significant segment within the opioids market. While the injectable segment currently holds the largest revenue share, the oral segment is anticipated to grow at a CAGR of 2.1% to 2.5% over the forecast period, driven by the approval of new opioid tablets and formulations[1][4].

Pricing and Cost Analysis

The cost of MS CONTIN ER varies based on the dosage and the pharmacy. Here are some approximate prices for different strengths of MS CONTIN ER:

  • 15 mg/8 to 12 hr: Around $492.68 for 100 tablets
  • 30 mg/8 to 12 hr: Around $927.65 for 100 tablets
  • 60 mg/8 to 12 hr: Around $1,801.07 for 100 tablets
  • 100 mg/8 to 12 hr: Around $2,662.03 for 100 tablets
  • 200 mg/8 to 12 hr: Around $4,867.31 for 100 tablets[2].

These prices are subject to variations due to stock shortages and other market factors.

Distribution Channels

The retail pharmacy segment leads the market with the maximum market share of 38% in 2023. This segment is expected to continue its dominance, although other distribution channels, such as online pharmacies, are also growing[1].

Competitive Landscape

The opioids market is highly competitive, with several key players including pharmaceutical companies like Teva, which has been involved in significant settlements and market movements. For instance, in January 2023, Teva announced a nationwide opioids settlement, which reflects the complex legal and regulatory environment surrounding opioids[1].

Regulatory Environment

The regulatory environment for opioids is stringent due to concerns about abuse and addiction. For example, the FDA has approved various abuse-deterrent formulations, and there are regulations requiring pharmacists to substitute high-potency, high-risk (HPHR) opioids with abuse-deterrent opioids (ADOs) when possible[5].

Future Outlook

Given the growing demand for effective pain management solutions, particularly in acute and chronic pain settings, the market for ER/long-acting opioids like MS CONTIN ER is expected to continue growing. Advancements in pharmacokinetics and patient-centric treatment approaches are driving this growth. However, the market will also be influenced by regulatory changes, legal settlements, and the ongoing need to balance pain management with opioid safety and abuse prevention.

Key Takeaways

  • Market Growth: The global opioids market, including MS CONTIN ER, is expected to grow at a CAGR of 1.4% from 2023 to 2030.
  • Regional Dominance: North America currently leads the market, but the Asia-Pacific region is expected to grow at the fastest CAGR.
  • Application: Pain relief is the primary application, with the anesthesia segment also showing significant growth.
  • Route of Administration: Oral formulations like MS CONTIN ER are expected to grow at a CAGR of 2.1% to 2.5%.
  • Pricing: Prices vary by dosage and pharmacy, with significant costs associated with higher strengths.
  • Distribution: Retail pharmacies dominate the distribution channels.
  • Regulatory Environment: Stringent regulations and the need for abuse-deterrent formulations are key factors.

FAQs

1. What is MS CONTIN ER used for? MS CONTIN ER is used for the management of moderate to severe pain that requires continuous, around-the-clock opioid analgesia, particularly in opioid-tolerant patients.

2. How is the global opioids market expected to grow? The global opioids market is expected to grow at a CAGR of 1.4% from 2023 to 2030, with the ER/long-acting opioids segment growing at a CAGR of 1.7%.

3. What is the current market share of North America in the opioids market? North America currently holds the highest market share of approximately 45.13% in the global opioids market.

4. How does the pricing of MS CONTIN ER vary? The pricing of MS CONTIN ER varies significantly based on the dosage strength, ranging from around $492.68 for 100 tablets of the 15 mg strength to around $4,867.31 for 100 tablets of the 200 mg strength.

5. What are the key distribution channels for MS CONTIN ER? The retail pharmacy segment leads the market with the maximum market share, although other distribution channels are also growing.

Sources

  1. Biospace: Opioids Market Size to Worth Around USD 26.78 Billion by 2034
  2. Drugs.com: MS Contin Prices, Coupons, Copay Cards & Patient Assistance
  3. FDA: MS CONTIN (morphine sulfate controlled-release) Tablets CII
  4. Grandview Research: Opioids Market Size, Share & Growth Analysis Report, 2030
  5. Mass.gov: Actuarial Analysis of the Drug Formulary Commission's Abuse Deterrent Drug Formulary

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.